about
Antileukotriene agents compared with placebo in children and adults with mild asthmaLeukotrienes in pulmonary arterial hypertensionEmerging role of antileukotriene therapy in allergic rhinitisImprovement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trialPersonal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthmaNational Athletic Trainers' Association position statement: management of asthma in athletes.The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.International consensus on (ICON) pediatric asthmaFor and against. Should steroids be the first line treatment for asthma?Recent advances: Respiratory medicine.Leukotrienes, leukotriene receptor antagonists, and rhinitis.Novel therapy for asthma.Leukotriene receptor antagonist therapyCurrent treatment of asthma--focus on leukotrienes.Recent advances in the diagnosis of Churg-Strauss syndrome.Antileukotrienes in clinical development for asthma.Second-generation antihistamines in asthma therapy: is there a protective effect?Adenosine monophosphate bronchial provocation and the actions of asthma therapy.CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Plasticity in mast cell responses during bacterial infections.A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmaticsAdd-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotypeLeukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma.Montelukast in allergic rhinitis: a systematic review and meta-analysis.Chronic urticaria: Indian context-challenges and treatment options.Management of asthma in adultsLeukotriene modifiers in the treatment of asthma in children.Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy.Montelukast medicines of today and tomorrow: from molecular pharmaceutics to technological formulations.Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older.Is montelukast effective and well tolerated in the management of asthma in young children?: Part A: Evidence-based answer and summary.Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma.Cutaneous lesions of Churg-Strauss syndrome associated with montelukast therapy.Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma.Clarithromycin, montelukast, and pentoxifylline combination treatment ameliorates experimental neonatal hyperoxic lung injury.Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast.
P2860
Q24187545-FFD6FC64-592D-424F-83D5-C6D069A72927Q26853496-7258D662-A27E-402D-BEC9-014D52745ADBQ28191844-1794EA30-E375-4F77-9325-2703AEFDBBABQ28192038-D8DEF074-71B7-4705-A1FD-FED3E6BEE9D4Q28766354-AADF4AF5-F5CB-4E6B-AA1A-CF07E7384454Q28769235-04824704-0582-43FF-B197-6A869E50828BQ30234961-AC9A5FCF-B43C-4D1E-98F4-FE57BF5FA390Q30393965-DA667CE2-2C24-4FB2-A9B2-01F25BE71DE9Q33807137-89D45547-DA77-441A-869F-1E547BFBDDA6Q33808282-DFDCE863-4E2C-4C6A-BAE5-4DF6F5B4FD6CQ33937511-86C9C092-A20B-4255-A9EB-AA2F9DE6DDFFQ34074657-4B09CC79-4DCC-455C-8646-19252A2F7D10Q34086351-8993D890-348B-42A1-946A-D341873A5380Q34181970-633FDD3D-BCC9-4D4E-BF39-03BBD71FE2F6Q34462800-4FE5DF98-A4F5-46B5-AA1F-798F189A5C20Q34481959-464E99D8-6DF1-4CBE-9B7A-AECC3E81C526Q34544512-28FAB473-0245-42DF-ACBA-8147CC049672Q35076739-58A78DDC-10CD-4FEB-BAC3-FECC5FE2DCBEQ35718619-40DA97AF-F817-48BE-A1DC-0FDB1CE857ACQ35767129-B2F1AE6B-2A19-446B-8FAE-4AAD42865EE9Q35825361-35D53E17-FA5B-4ABE-BEEE-FA9D2AA9075CQ35825639-00E54A57-04B4-4BC6-9057-8E34F3BFBEFDQ35825743-F0B5B6EB-E178-444C-84FC-A43A1C2FC2CEQ36609797-33013701-F761-48DF-843C-AF0365F2AA2BQ37239677-F5EE36A4-B905-4B0F-8E94-CA498AFC455AQ37460865-AAE4370E-DD0A-4F61-A1B7-46C469EA5DAAQ37613312-489F5121-382C-49AB-8591-3BA85A63D64EQ38733745-45D4EA08-00C2-4999-ABDA-6666BF7E9E49Q38787365-3E594ED9-8BA3-4E90-BFC4-50B25ECF523BQ40700694-E2A6B22A-0667-4360-85CF-5F7D5D999C41Q42426143-387CAFE5-72FA-4D44-A4CF-23E44FC1DD77Q42997336-38D3BFEB-5496-41C1-9CC3-91DCD64F2380Q43612606-DE3AE4D3-FF1F-41D5-9E90-B73E65011BB1Q44122737-674B432B-EAC9-4D62-BEEA-45113B6E4466Q44232436-632178F3-41F8-4A22-93C1-1EA3E572C1B5Q44474627-9F381440-AD42-4A6D-85A7-D5E26CAEE6C5Q44925206-5A976AA4-21CE-45B5-B4BC-6A1ACD4ADF78Q46526812-ECAC1560-08B3-4D3C-9285-31C3DEF56889Q49685370-F1AD61B7-99E8-4523-AA47-916C20C6F36AQ51663926-F2F07A70-B6E4-4D8E-B4D4-91B4C1676013
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Leukotriene-receptor antagonists.
@ast
Leukotriene-receptor antagonists.
@en
Leukotriene-receptor antagonists.
@nl
type
label
Leukotriene-receptor antagonists.
@ast
Leukotriene-receptor antagonists.
@en
Leukotriene-receptor antagonists.
@nl
prefLabel
Leukotriene-receptor antagonists.
@ast
Leukotriene-receptor antagonists.
@en
Leukotriene-receptor antagonists.
@nl
P1433
P1476
Leukotriene-receptor antagonists.
@en
P2093
B J Lipworth
P356
10.1016/S0140-6736(98)09019-9
P407
P577
1999-01-01T00:00:00Z